CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 32 enrolled
Drug / intervention
Carbidopa +1 moredrug
Likely dose
Carbidopa 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00685919
NCT00685919Phase 3Completed
CompareCT.gov

Kidney Dopamine Effects on Urinary Sodium Excretion in Postural Tachycardia Syndrome

Vanderbilt University·interventional·Posted May 29, 2008·Updated Jan 24, 2022

In Brief

A Phase 3 clinical trial evaluating Carbidopa and Placebo for Postural Tachycardia Syndrome and Orthostatic Intolerance. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The purpose of the proposed research is to determine how changes in kidney dopamine (DA) activity influence urinary sodium excretion. We will decrease DA activity in the kidney by inhibiting DA synthesis via carbidopa administration. We want to compare findings in normal volunteers and in patients with postural tachycardia syndrome (POTS). We will test the null hypothesis (Ho) that the effects of oral carbidopa administration on urinary sodium excretion will not differ between patients with POTS and healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostural Tachycardia Syndrome, Orthostatic Intolerance
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 29, 2008
Enrollment StartMay 1, 2008
Primary CompletionJul 1, 2020
Study CompletionDec 1, 2021
TodayJul 2, 2026
Enrollment to primary: 12.2 yearsPosted 18.1 years ago

Interventions

Carbidopadrug

200 mg every 6 hours for 5 doses given orally

Placebodrug

every 6 hours for 5 doses, given orally, and matching Carbidopa